Life Science Strategy Summit on IP & Exclusivity returns to Munich with 15% IPKat readers’ discount

Kat-cafè in Munich

The Katfriends at Kisaco Research are always busy organizing industry-focused events in the IP field. Readers interested in the life science sector will be pleased to learn that this year’s Life Science Strategy Summit on IP & Exclusivity will take place in Munich (Germany) between 8 and 10 October 2024.

This conference intends to gather the leading pharmaceutical and biotech professionals for 3 days of practical discussion on the protection of pharmaceutical drugs based on patent and regulatory exclusivities. Represented companies include, amongst others: Bayer, Haleon, Polpharma, Novo Nordisk, Amgen, Fresenius Kabi, Regeneron, and Sandoz.

According to the organizers, the 2024 edition’s highlights include:

• A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
• The intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
• The requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
• The ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.

An up-to-date agenda can be viewed here.

Once again, this year’s summit will host the pre-event SPC & PTE Forum 2024, allowing a mixed audience of in-house counsel, private practice members and key regulators to discuss the strategies and updates concerning SPCs and PTEs.

IPKat readers are entitled to a 15% discount in the registration fee using VIP code IPKAT_SM at checkout. For further information and to register, click here.